Companies/Kura Oncology, Inc.

Company profile

Kura Oncology, Inc.

NASDAQ: KURA · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001422143Reports USD

#396 of 1,418 Healthcare companies by revenue70th-percentile growth

EA Score

39D

FH 36DQ 36GM —SS 69

v0.1 · 55/100 weight · provisional

↑ market scale, workforce scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

$71.6M

Rev growth YoY (TTM)

+5.4%

Net income (FY)

-$278.7M

Employees

260

as of 2026-08-10

Market cap

$849.6M

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$67.5M$67.5M2025

Net income-$278.7M-$278.7M2025

Operating income-$303.6M-$303.6M2025

Total assets$738.4M$738.4M2025

Liabilities$564.2M$564.2M2025

Equity$174.1M$174.1M2025

Revenue trend

FY2025 – FY2025 · USD

FY25

$53.9M

FY24

$67.5M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Collaboration Revenue97%

Product3%

By geography

Not disclosed.

The read

What is Kura Oncology, Inc.’s revenue?

Kura Oncology, Inc. booked $67.5M in FY2025 revenue, growing 25% year over year — faster than most Healthcare companies we track, at a -412.9% net margin.

Peers · Healthcare

Rockwell Medical, Inc.60C Vir Biotechnology, Inc.48D Intellia Therapeutics, Inc.57C Praxsyn Corporation——Pro-Dex, Inc.86A Exagen Inc.55C

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOTroy Wilson

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: KURA

Employees260

IPO date2015-09-16

Latest filings

8-K2026-06-04 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-10 10-K2026-03-05 8-K2026-03-05 8-K2026-01-29 8-K2026-01-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.